• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者对二线姑息化疗利弊信息的偏好及其肿瘤医生对这些偏好的认知

Patients' Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences.

作者信息

Oostendorp Linda J M, Ottevanger Petronella B, van de Wouw Agnes J, Honkoop Aafke H, Los Maartje, van der Graaf Winette T A, Stalmeier Peep F M

机构信息

Department for Health Evidence, Radboudumc, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.

Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands.

出版信息

J Cancer Educ. 2016 Sep;31(3):443-8. doi: 10.1007/s13187-015-0845-9.

DOI:10.1007/s13187-015-0845-9
PMID:25985960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4988994/
Abstract

Communication about palliative treatment options requires a balance between providing patients with sufficient information and not providing unwanted information. Surveys have indicated that many patients with advanced cancer express a wish to receive detailed information. In this prospective multicenter study, the information desire of patients with advanced breast or colorectal cancer was further investigated by offering treatment-related information to patients using a decision aid (DA). In addition, this study explored oncologists' awareness of their patients' information desire. Seventy-seven patients with advanced breast or colorectal cancer facing the decision whether to start second-line palliative chemotherapy were offered a DA by a nurse. This DA contained information on adverse events, tumor response, and survival. The nurse asked the patient whether each information item was desired. Ninety-five percent of patients chose to receive information on adverse events, 91 % chose to receive information on tumor response, and 74 % chose to receive information on survival. Oncologists' judgment of patients' information desire was 100, 97, and 81 %, respectively. For all three information items together, oncologists correctly judged the information desire of 62 % of patients. This study confirms that many patients with advanced cancer wish to receive detailed information on the benefits and risks of palliative treatment options when the information is actually available. Oncologists were adequately aware of this high information desire, but had some difficulty judging the information desire of individual patients. A stepped approach to giving information ("preview, ask, tell, ask") may help to better meet patients' information needs.

摘要

关于姑息治疗方案的沟通需要在为患者提供足够信息和不提供不必要信息之间取得平衡。调查表明,许多晚期癌症患者表示希望获得详细信息。在这项前瞻性多中心研究中,通过使用决策辅助工具(DA)向患者提供与治疗相关的信息,进一步调查了晚期乳腺癌或结直肠癌患者的信息需求。此外,本研究还探讨了肿瘤学家对患者信息需求的认知情况。77名面临是否开始二线姑息化疗决策的晚期乳腺癌或结直肠癌患者由一名护士提供了决策辅助工具。该决策辅助工具包含有关不良事件、肿瘤反应和生存情况的信息。护士询问患者是否希望了解每个信息项目。95%的患者选择接收有关不良事件的信息,91%选择接收有关肿瘤反应的信息,74%选择接收有关生存情况的信息。肿瘤学家对患者信息需求的判断分别为100%、97%和81%。对于所有三个信息项目,肿瘤学家正确判断了62%患者的信息需求。本研究证实,许多晚期癌症患者希望在实际有信息可用时,获得有关姑息治疗方案的益处和风险的详细信息。肿瘤学家充分意识到这种对信息的高需求,但在判断个别患者的信息需求方面存在一些困难。一种分阶段提供信息的方法(“预览、询问、告知、询问”)可能有助于更好地满足患者的信息需求。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3faa/4988994/672279b145cf/13187_2015_845_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3faa/4988994/672279b145cf/13187_2015_845_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3faa/4988994/672279b145cf/13187_2015_845_Fig1_HTML.jpg

相似文献

1
Patients' Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences.患者对二线姑息化疗利弊信息的偏好及其肿瘤医生对这些偏好的认知
J Cancer Educ. 2016 Sep;31(3):443-8. doi: 10.1007/s13187-015-0845-9.
2
Expected survival with and without second-line palliative chemotherapy: who wants to know?接受和不接受二线姑息化疗的预期生存率:谁想知道?
Health Expect. 2015 Dec;18(6):2903-14. doi: 10.1111/hex.12275. Epub 2014 Oct 10.
3
Shared decision making about palliative chemotherapy: A qualitative observation of talk about patients' preferences.关于姑息性化疗的共同决策:对患者偏好讨论的定性观察
Palliat Med. 2017 Jul;31(7):625-633. doi: 10.1177/0269216316676010. Epub 2016 Oct 26.
4
Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial.二线姑息性化疗的决策辅助工具:一项随机II期多中心试验。
BMC Med Inform Decis Mak. 2017 Aug 31;17(1):130. doi: 10.1186/s12911-017-0529-y.
5
Assessing the information desire of patients with advanced cancer by providing information with a decision aid, which is evaluated in a randomized trial: a study protocol.采用决策辅助工具为晚期癌症患者提供信息,并对其信息需求进行评估的随机试验:研究方案。
BMC Med Inform Decis Mak. 2011 Feb 14;11:9. doi: 10.1186/1472-6947-11-9.
6
How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter.肿瘤学家在医疗问诊中的治疗决策背景下,如何向复发性卵巢癌女性传达信息。
Health Expect. 2015 Oct;18(5):1066-80. doi: 10.1111/hex.12079. Epub 2013 May 13.
7
Inventory of oncologists' unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer.肿瘤学家在支持转移性结直肠癌姑息治疗决策方面工具未满足需求的清单。
BMC Med Inform Decis Mak. 2018 Dec 14;18(1):132. doi: 10.1186/s12911-018-0712-9.
8
Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy.晚期乳腺癌患者对姑息性化疗决策的看法。
J Clin Oncol. 2006 Mar 1;24(7):1090-8. doi: 10.1200/JCO.2005.01.9208.
9
Breast Cancer Patients' Preferences for Truth Versus Hope Are Dynamic and Change During Late Lines of Palliative Chemotherapy.晚期姑息化疗中,乳腺癌患者对真相与希望的偏好是动态变化的。
J Pain Symptom Manage. 2019 Apr;57(4):746-752. doi: 10.1016/j.jpainsymman.2018.12.336. Epub 2019 Jan 11.
10
Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer.转移性乳腺癌患者一线化疗决策辅助工具的开发与评估
Health Expect. 2008 Mar;11(1):35-45. doi: 10.1111/j.1369-7625.2007.00470.x.

引用本文的文献

1
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy for Refractory Colorectal Liver Metastasis: A Systematic Review.载药微球伊立替康(DEBIRI)治疗难治性结直肠癌肝转移:一项系统评价
Cureus. 2023 Dec 6;15(12):e50072. doi: 10.7759/cureus.50072. eCollection 2023 Dec.
2
Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey study.晚期癌症患者不希望了解预后特征的多中心调查研究。
BMC Cancer. 2022 Sep 1;22(1):941. doi: 10.1186/s12885-022-09911-8.
3
The use of PROMs and shared decision-making in medical encounters with patients: An opportunity to deliver value-based health care to patients.

本文引用的文献

1
Decision aids for people facing health treatment or screening decisions.为面临医疗治疗或筛查决策的人们提供的决策辅助工具。
Cochrane Database Syst Rev. 2017 Apr 12;4(4):CD001431. doi: 10.1002/14651858.CD001431.pub5.
2
Stop the silent misdiagnosis: patients' preferences matter.杜绝隐匿误诊:患者的偏好至关重要。
BMJ. 2012 Nov 8;345:e6572. doi: 10.1136/bmj.e6572.
3
Talking with patients about dying.与患者谈论死亡。
在与患者的医疗接触中使用患者报告结局测量指标(PROMs)和共同决策:为患者提供基于价值的医疗服务的契机。
J Eval Clin Pract. 2020 Apr;26(2):524-540. doi: 10.1111/jep.13321. Epub 2019 Dec 15.
4
The Stage IV Shuffle: Elusiveness of Straight Talk About Advanced Cancer.IV 期洗牌:晚期癌症直言不讳的难以捉摸。
J Gen Intern Med. 2019 Nov;34(11):2637-2642. doi: 10.1007/s11606-019-05158-5. Epub 2019 Aug 5.
5
Using PROMs during routine medical consultations: The perspectives of people with Parkinson's disease and their health professionals.在常规医疗咨询中使用 PROMs:帕金森病患者及其卫生专业人员的观点。
Health Expect. 2019 Oct;22(5):939-951. doi: 10.1111/hex.12899. Epub 2019 Jun 14.
6
The availability and effectiveness of tools supporting shared decision making in metastatic breast cancer care: a review.支持转移性乳腺癌护理中共同决策的工具的可用性和有效性:综述。
BMC Palliat Care. 2018 May 11;17(1):74. doi: 10.1186/s12904-018-0330-4.
7
Unpacking cancer patients' preferences for information about their care.剖析癌症患者对自身护理信息的偏好。
J Psychosoc Oncol. 2018 Jan-Feb;36(1):1-18. doi: 10.1080/07347332.2017.1357666. Epub 2017 Nov 21.
8
Factors Which Influence Owners When Deciding to Use Chemotherapy in Terminally Ill Pets.绝症宠物主人决定是否使用化疗时的影响因素。
Animals (Basel). 2017 Mar 7;7(3):18. doi: 10.3390/ani7030018.
N Engl J Med. 2012 Oct 25;367(17):1651-2. doi: 10.1056/NEJMe1211160.
4
Patients' expectations about effects of chemotherapy for advanced cancer.晚期癌症化疗效果的患者期望。
N Engl J Med. 2012 Oct 25;367(17):1616-25. doi: 10.1056/NEJMoa1204410.
5
Discussions of life expectancy moderate relationships between prognosis and anxiety or depression in men with advanced cancer.讨论预期寿命可以在一定程度上调节晚期癌症男性患者的预后与焦虑或抑郁之间的关系。
J Palliat Med. 2012 Jan;15(1):99-105. doi: 10.1089/jpm.2011.0249.
6
Preferences for cancer treatments: an overview of methods and applications in oncology.癌症治疗偏好:肿瘤学中方法和应用概述。
Ann Oncol. 2012 May;23(5):1104-1110. doi: 10.1093/annonc/mdr559. Epub 2012 Jan 10.
7
Walking a tightrope: oncologists' perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter.走钢丝:肿瘤学家在医疗就诊期间为复发性卵巢癌(ROC)女性提供信息的观点。
Support Care Cancer. 2012 Oct;20(10):2327-33. doi: 10.1007/s00520-011-1344-0. Epub 2011 Dec 14.
8
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.蒽环类和紫杉类预处理的晚期乳腺癌患者姑息化疗的疗效和安全性:系统评价。
Lancet Oncol. 2011 Oct;12(11):1053-61. doi: 10.1016/S1470-2045(11)70045-6. Epub 2011 May 27.
9
Assessing the information desire of patients with advanced cancer by providing information with a decision aid, which is evaluated in a randomized trial: a study protocol.采用决策辅助工具为晚期癌症患者提供信息,并对其信息需求进行评估的随机试验:研究方案。
BMC Med Inform Decis Mak. 2011 Feb 14;11:9. doi: 10.1186/1472-6947-11-9.
10
Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.系统评价二线伊立替康单药治疗晚期结直肠癌的获益与风险。
Anticancer Drugs. 2010 Sep;21(8):749-58. doi: 10.1097/CAD.0b013e32833c57cf.